UPDATE : Friday, July 10, 2020
상단여백
[ASCO 2020 ⑥] Alteogen confirms safety, efficacy of HER2 breast cancer therapy
Alteogen said that its antibody-drug conjugate (ADC) ALT-P7 for patients wi...
by Shim Hyun-tai  |  2020-06-04 17:35
라인
[ASCO 2020 ⑤] Lunit opens possibility of personalized cancer treatment with AI platform
Lunit has become Korea’s only AI-based medical image analytics company to p...
by Lee Han-soo  |  2020-06-04 16:25
라인
[ASCO 2020 ④] MedPacto's Vactosertib combo treatment for desmoid tumors proved safe
MedPacto said the combination of its small molecule TGF-B inhibitor, Vactos...
by Shim Hyun-tai  |  2020-06-03 17:20
라인
[ASCO 2020 ③] Genexine’s combo therapy for breast cancer proves safety
Genexine said that the combination therapy of its Hyleukin-7 and MSD’s Keyt...
by Shim Hyun-tai  |  2020-06-02 17:14
라인
[ASCO 2020 ②] GC confirms safety, efficacy of anti-EGFR monoclonal antibody
GC has come up with optimal interim results for its phase 1b/2a clinical tr...
by Lee Han-soo  |  2020-06-02 11:20
라인
[ASCO 2020 ①] Samsung Bioepis’ anticancer biosimilar shows equal quality to original drug
Samsung Bioepis headquarters in Songdo, Incheon. Samsung Bioepis said tha...
by Lee Han-soo  |  2020-06-01 16:14
여백
여백
여백
Back to Top